Multicure Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 2.04 Cr
- Company Age 29 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 14.20%
- Profit Growth -28.98%
- Ebitda 53.44%
- Net Worth 67.05%
- Total Assets 126.38%
About Multicure Pharma
Multicure Pharma Private Limited (MPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 31 March 1995 and has a history of 29 years and ten months. Its registered office is in Bangaluru, Karnataka, India.
The Corporate was formerly known as Multi Medicos Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.04 Cr, as per Ministry of Corporate Affairs (MCA) records.
Heeralal Sharma and Shashi Sharma serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U17297KA1995PTC103571
- Company No.
103571
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Mar 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Multicure Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shashi Sharma  | Managing Director | 12-Jun-2012 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Heeralal Sharma | Additional Director | 18-Aug-2021 | Current |
Financial Performance of Multicure Pharma.
Multicure Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.2% increase. The company also saw a substantial fall in profitability, with a 28.98% decrease in profit. The company's net worth Soared by an impressive increase of 67.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Multicure Pharma?
In 2023, Multicure Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Maxwell & Higgs (India) Private LimitedHeeralal Sharma and Shashi Sharma are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Multicure Pharma?
Unlock and access historical data on people associated with Multicure Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Multicure Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Multicure Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
